These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21401356)

  • 21. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function.
    Lajer M; Tarnow I; Michelson AD; Jorsal A; Frelinger AL; Parving HH; Rossing P; Tarnow L
    Platelets; 2010; 21(7):525-32. PubMed ID: 20701458
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal autoregulation and passive pressure-flow relationships in diabetes and hypertension.
    Hill JV; Findon G; Appelhoff RJ; Endre ZH
    Am J Physiol Renal Physiol; 2010 Oct; 299(4):F837-44. PubMed ID: 20660017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of selective inhibition of thromboxane synthesis on renal function in diabetic nephropathy.
    Kontessis PS; Jones SL; Barrow SE; Stratton PD; Alessandrini P; De Cosmo S; Ritter JM; Viberti GC
    J Lab Clin Med; 1993 Mar; 121(3):415-23. PubMed ID: 8445289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longitudinal evaluation of renal function in non-insulin-dependent diabetic patients with early nephropathy: effects of angiotensin-converting enzyme inhibition.
    Vora JP; Leese GP; Peters JR; Owens DR
    J Diabetes Complications; 1996; 10(2):88-93. PubMed ID: 8777336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mildly altered vascular homeostasis in early stage of CKD.
    Futrakul N; Futrakul P
    Ren Fail; 2009; 31(7):538-43. PubMed ID: 19839847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kidney involvement and disease in patients with diabetes.
    Chiarelli F; Trotta D; Verrotti A; Mohn A
    Panminerva Med; 2003 Mar; 45(1):23-41. PubMed ID: 12682618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ACE-I and ARBs in early diabetic nephropathy.
    Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
    J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal microvascular disease in an aging population: a reversible process?
    Futrakul N; Futrakul P
    Ren Fail; 2008; 30(4):353-6. PubMed ID: 18569906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of anti-hypertensive therapy in diabetic patients with and without reduced renal function.
    Sweileh WM; Sawalha AF; Zyoud SH; Al-Jabi SW; Tameem EJ
    Saudi J Kidney Dis Transpl; 2010 Jul; 21(4):652-9. PubMed ID: 20587868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan): Rationale and study design.
    Shikata K; Haneda M; Koya D; Suzuki Y; Tomino Y; Yamada K; Maeda S; Kawakami N; Uzu T; Nishimura M; Sato C; Ogawa D; Makino H;
    Diabetes Res Clin Pract; 2010 Feb; 87(2):228-32. PubMed ID: 19889469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular homeostasis and angiogenesis determine therapeutic effectiveness in type 2 diabetes.
    Futrakul N; Futrakul P
    Int J Vasc Med; 2011; 2011():971524. PubMed ID: 21748023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early stage of vascular disease and diabetic kidney disease: an under-recognized entity.
    Futrakul N; Chanakul A; Futrakul P; Deekajorndech T
    Ren Fail; 2015; 37(8):1243-6. PubMed ID: 26365595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarker for early renal microvascular and diabetic kidney diseases.
    Futrakul N; Futrakul P
    Ren Fail; 2017 Nov; 39(1):505-511. PubMed ID: 28494191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vascular response to vasodilator treatment in microalbuminuric diabetic kidney disease.
    Futrakul N; Futrakul P
    World J Nephrol; 2013 Nov; 2(4):125-8. PubMed ID: 24255895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urgent call for reconsideration of chronic kidney disease.
    Futrakul N; Futrakul P
    World J Nephrol; 2012 Dec; 1(6):155-9. PubMed ID: 24175254
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.